GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GlaxoSmithKline is on track to deliver a much better performance in 2022 as investors see evidence of the potential in both arms of the business, according to Berenberg. Appreciation of the consumer healthcare business should improve as it moves towards demerger from the pharma side, while data from trials should show that the new pharma-led GSK can deliver on its targets.

GlaxoSmithKline's appeal to become much clearer in 2022 says broker

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) entered a drug development deal with GlaxoSmithKline Plc (NYSE: GSK), under which GSK will develop and market Arrowhead's potential treatment for patients with fatty liver disease NASH. Under the pact, Arrowhead would get an upfront payment of $120 million and is in line for an extra $30 million to start a Phase 2 trial and another $100 million if Phase 2 is successful and leads to a Phase 3.

GlaxoSmithKline Pens $1B Pact For NASH Candidate With Arrowhead

Viatris

These stocks are unlikely to beat the market, but they're great for dividend income.

2 Cheap Pharma Stocks That Pay A Tidy Dividend

AstraZeneca

Bristol-Myers

Eli Lilly

Pfizer

Of the top nine members of Big Pharma with high dividend yields, Eli Lilly and Co. ( LLY , Financial) brings up the rear at 1.32%. But that hardly tells the full story.

Look to Big Pharma for Healthy Dividends

Vir Biotechnology

Glaxo (GSK) and Vir Biotechnology (VIR) sign purchase contract with the U.S. government to supply doses of sotrovimab worth approximately $1 billion by next month.

Glaxo (GSK), Vir to Supply COVID Drug Sotrovimab to Government

GSK vs. NVO: Which Stock Is the Better Value Option?

GSK or NVO: Which Is the Better Value Stock Right Now?

Britain's GlaxoSmithKline plc (LON: GSK) announced in a joint statement with the U.S. based Vir Biotechnology Inc (NASDAQ: VIR) on Wednesday that the U.S. government had agreed to buy about $1.0 billion worth of its antibody-based COVID-19 treatment. U.S. wants GSK to deliver the doses by December 17th   The number of doses of Sotrovimab […] The post U.S. places a sizable order for GSK-Vir's COVID-19 treatment appeared first on Invezz.

U.S. places a sizable order for GSK-Vir's COVID-19 treatment

The United States government has signed contracts worth about $1 billion to secure the antibody-based COVID-19 treatment developed by GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR). GSK said the deal brought the total number of doses secured for the treatment, sotrovimab, to more than 750,000 globally.

US Government Agrees To Purchase GSK-Vir Biotech's COVID-19 Antibody Doses Worth $1B

The U.S. government has agreed to buy more doses of an antibody drug for the early treatment of Covid-19 developed by GlaxoSmithKline and Vir Biotechnology bringing its total order to nearly $1 billion for a treatment found to reduce the risk of hospitalization.

The Wall Street Journal: U.S. government will buy more of GlaxoSmithKline and Vir's COVID antibody drug

Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2021/2022, which should boost the top line in the long term

4 Reasons Why You Should Add Glaxo (GSK) to Your Portfolio

Glaxo (GSK) and Vir announce non-inferiority of intramuscular administration of sotrovimab compared to intravenous administration in reducing hospitalization or death as an early treatment of mild-to-moderate COVID-19.

Glaxo (GSK), Vir Intramuscular Sotrovimab Meets Study Endpoint

WARREN, N.J., Nov. 15, 2021 /PRNewswire/ -- GlaxoSmithKline (LSE: GSK) (NYSE: GSK) – This Thanksgiving, bring more holiday cheer and less heartburn fear to the table.

TUMS® Provides #TUMSworthy Holiday Hacks for Heartburn Inducing Moments this Thanksgiving with the Help of Comedian Ronny Chieng

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced topline data from COMET-TAIL Phase 3 trial evaluating sotrovimab delivered via Intramuscular (IM) administration compared to IV administration in high-risk COVID-19 patients. The trial achieved its primary endpoint, demonstrating that IM administration of sotrovimab was non-inferior to intravenous (IV) administration for the early treatment of mild-to-moderate COVID-19 up to seven days after symptom onset.

GSK, Vir's Intramuscularly-Administered Sotrovimab Shows Efficacy At Par With IV Route In COVID-19

A Phase III trial of intramuscular administration of sotrovimab met its primary endpoint of non-inferiority to intravenous administration for early treatement of COVID-19 in high-risk adults and adolescents, GlaxoSmithKline GSK, +0.12% GSK, +0.36% and Vir Biotechnology VIR, +2.54% said. The companies noted the trial was conducted during the height of the Delta variant in Florida.

Glaxo and Vir COVID-19 treatment meets endpoint in Phase III trial

AbbVie

American Electric Power Company

Cardinal Health

Canadian Imperial Bank of Commerce

Cisco Systems

Diageo

Genuine Parts

Huntington Bancshares

Iron Mountain

Illinois Tool Works

Leggett & Platt

Realty Income Corp

Philip Morris

TotalEnergies SE

ViacomCBS

WestRock

Exxon Mobil

Dividend Income Summary: Bert's October 2021 Report

Is (GSK) Outperforming Other Medical Stocks This Year?

Is GlaxoSmithKline plc (GSK) Outperforming Other Medical Stocks This Year?

GlaxoSmithKline plc (NYSE: GSK) announced positive results from the ASCEND program comprised of five Phase 3 studies assessing daprodustat for anemia due to chronic kidney disease (CKD). Daprodustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI).

GlaxoSmithKline Spotlights Encouraging Data For Anemia Drug

LONDON, Nov. 5, 2021 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive results from the Phase III ASCEND (Anaemia Studies in Chronic Kidney Disease: Erythropoiesis via a novel prolyl hydroxylase inhibitor Daprodustat) programme for daprodustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), during a presentation at the American Society of Nephrology's Kidney Week 2021. The positive primary efficacy and safety results confirm the potential for daprodustat to be a new oral treatment for patients with anaemia due to chronic kidney disease (CKD) in both non-dialysis and dialysis settings.

GSK announces positive Phase III efficacy and safety data for daprodustat in patients with anaemia due to chronic kidney disease

Nikola

Shake Shack

Markets continued their rally into the weekend, after a stronger-than-expected employment report for the month of October.

Friday Afternoon Analyst Upgrades and Downgrades: GlaxoSmithKline, Nikola, Shake Shack and More

VOXX International Corporation Class A

Kahn Brothers (Trades, Portfolio), the firm founded by the late Irving Kahn and his brothers Thomas Graham Kahn and Alan Kahn, disclosed this week that its top four buys during the third quarter were Pfizer Inc. ( PFE , Financial), VOXX International Corp. ( VOXX , Financial), BP PLC ( BP , Financial) and GlaxoSmithKline PLC ( GSK , Financial).

Kahn Brothers' Top 4 Buys in the 3rd Quarter

Bank of Nova Scotia

Chimera Investment

Coinbase

Eastman Chemical

Gap Inc

Coca-Cola

MDU Resources Group

Medical Properties Trust

NetApp

Oracle

Occidental Petroleum

South32 Ltd

Visa

In October, we (my wife and I) received a total of $966.97 of dividend income.

Dividend Income Summary: Lanny's October 2021 Summary

Glaxo's (GSK) revenues benefit from the recovery in sales of products across all segments and additional revenues from the supply of pandemic adjuvant to partners.

Glaxo (GSK) Beats on Q3 Earnings, Gives Improved EPS View

GlaxoSmithKline plc (GSK) CEO Emma Walmsley on Q3 2021 Results - Earnings Call Transcript

GlaxoSmithKline Plc (NYSE: GSK), in its Q3 earnings release, revealed that it is stopping the development of otilimab in COVID-19 in patients who are at least 70 years old.  The Company decided because their already-approved monoclonal antibody Xevudy “plays an important role as a treatment for mild-to-moderate COVID-19 in high-risk adult and pediatric patients,” according to a company statement.

GlaxoSmithKline Drops Research On Otilimab In COVID-19

Glaxo (GSK) beats earnings as well as revenues estimates in the third quarter of 2021. Stock up.

Glaxo (GSK) Beats Earnings and Revenues Estimates in Q3

News for GlaxoSmithKline Stock (GSK)